Clinical Study Startup Checklist: FDA and ICH E6(R3) Requirements to Prevent Costly Trial Delays

Starting a clinical trial involves navigating complex regulatory requirements and establishing systems that protect participants while ensuring data integrity. A 2025 FDA analysis found that 40% of clinical trial delays stem from inadequate startup procedures rather than scientific challenges. The consequences are significant: regulatory violations can trigger FDA warning letters, study suspensions, and millions in lost investment.

The ICH E6(R3) Good Clinical Practice guidelines, updated in September 2025, provide the international framework for conducting ethical, scientifically sound clinical research. Combined with FDA requirements, these guidelines establish mandatory procedures that must be in place before enrolling the first participant. This comprehensive checklist ensures your study startup meets all regulatory expectations while building a foundation for successful trial execution.

Pre-Study Documentation Requirements

Before any research activities begin, specific documentation must be complete and accessible for regulatory inspection. The Essential Documents framework from ICH GCP Section 8 defines three categories: documents required before trial commencement, during conduct, and after completion.

Investigational Product Documentation

Investigator’s Brochure serves as the foundational document describing the investigational product’s scientific rationale, preclinical data, and known safety profile. For sponsor-investigator trials, this may be substituted with:

• Expanded protocol background section containing minimum required information
• Basic product information brochure from commercial manufacturer
• Package leaflet or approved labeling for marketed products used in new indications

Sample Labels for investigational products must comply with FDA labeling requirements. Labels should include protocol identification, dosing instructions, storage conditions, and appropriate safety warnings. Keep copies of all label versions used throughout the study.

Protocol and Case Report Forms

Signed Protocol documentation includes the current IRB-approved version plus all amendments. Each investigator must sign the protocol to document agreement with procedures and responsibilities. Electronic signatures are acceptable if your system meets 21 CFR Part 11 requirements.

Case Report Forms (CRFs) capture all protocol-required data points. Whether paper-based or electronic, CRFs must be finalized before study startup. Key considerations include:

• Data fields align with protocol endpoints
• Source data verification procedures are defined
• Electronic systems include adequate audit trails
• Backup procedures exist for system failures

Financial and Legal Agreements

Financial Documentation encompasses all agreements between sponsors, investigators, and institutions. Maintain copies of contracts, budget agreements, payment schedules, and any cost-sharing arrangements. The FDA may review these during inspections to assess potential financial conflicts of interest.

Insurance Coverage documentation varies by jurisdiction. US-based studies typically rely on institutional coverage, while international sites may require specific clinical trial insurance policies.

Regulatory Approvals and Communications

Regulatory approval represents the formal authorization to proceed with human subject research. Multiple agencies and committees provide oversight, each with specific submission requirements and timelines.

IRB/Ethics Committee Approval

Initial Approval must be obtained before any research activities, including screening or recruitment. The approval letter should specifically reference:

• Protocol title and version number
• Approved consent form versions and dates
• Approval period and continuing review requirements
• Any special conditions or restrictions

IRB Composition documentation demonstrates the committee meets regulatory requirements for expertise, independence, and community representation. Most institutions maintain this centrally, but investigators should verify current composition.

FDA Authorization Requirements

IND (Investigational New Drug) applications are required for studies involving unapproved drugs or approved drugs used outside their labeled indication. The 30-day safety review period must expire before dosing the first participant.

IDE (Investigational Device Exemption) applies to studies of unapproved medical devices or approved devices used for unapproved purposes. Significant risk device studies require explicit FDA approval before initiation.

Clinical Trial Registration on ClinicalTrials.gov is mandatory for most interventional studies. Registration must occur before enrolling the first participant and include all required data elements defined in 42 CFR 11.

International Regulatory Considerations

For multi-national studies, each country’s regulatory authority requires separate notification or approval. Common requirements include:

• Health Canada Clinical Trial Regulations for Canadian sites
• EMA Clinical Trial Regulation (EU CTR) for European sites
• PMDA consultation for Japanese sites
• Local ethics committee approvals per national requirements

Personnel Qualifications and Training

Research team competency directly impacts participant safety and data quality. The ICH GCP guidelines specify training requirements for all personnel involved in clinical research activities.

Investigator Qualifications

Principal Investigator qualifications must be documented through current curriculum vitae, medical licenses, and specialty certifications. The CV should demonstrate:

• Relevant clinical experience in the therapeutic area
• Prior clinical research experience or formal training
• Current medical license without restrictions
• Adequate time commitment for the study

Sub-investigators require similar documentation proportional to their delegated responsibilities. Each must have qualifications appropriate for their assigned tasks.

Good Clinical Practice Training

GCP Training is mandatory for all personnel involved in clinical trial conduct, oversight, or management. The FDA recognizes two categories:

• FDA-regulated research GCP training for drug and device studies
• Behavioral/non-FDA regulated GCP training for other intervention studies

Training must be current (typically within 3 years) and documented before personnel begin study activities. Refresher training may be required for protocol amendments or after significant time gaps.

Study-Specific Training Documentation

Protocol Training ensures all team members understand study procedures, inclusion/exclusion criteria, and safety requirements. Document training through:

• Training logs with attendee signatures and dates
• Training materials including presentation slides or handouts
• Competency assessments for complex procedures
• Delegation of authority logs specifying each person’s responsibilities

Ongoing Training requirements include safety updates, protocol amendments, and new procedure training. Maintain records demonstrating all team members receive relevant updates promptly.

Essential Systems and Procedures

Operational systems established during startup determine the study’s ability to maintain compliance throughout execution. These systems must be validated and documented before participant enrollment begins.

Data Management Systems

Electronic Data Capture (EDC) systems must meet 21 CFR Part 11 requirements for electronic records and signatures. Key validation elements include:

• User access controls with unique identifiers and secure passwords
• Audit trails capturing all data changes with user identification and timestamps
• Data backup and recovery procedures with regular testing
• System validation documentation demonstrating intended functionality

Source Document Procedures define what constitutes source data and how it flows into case report forms. Establish clear procedures for source data verification and discrepancy resolution.

Safety Reporting Systems

Adverse Event Reporting procedures must align with FDA requirements and sponsor pharmacovigilance standards. Establish:

• AE assessment procedures including causality and severity determination
• Serious AE reporting timelines (typically 24 hours to sponsor)
• Regulatory reporting requirements for suspected unexpected serious adverse reactions
• Safety database access and training for study personnel

Data Safety Monitoring plans appropriate to the study risk level. Higher-risk studies may require formal Data Safety Monitoring Boards (DSMBs) with independent oversight authority.

Quality Assurance Procedures

Monitoring Plans define the frequency and extent of sponsor oversight activities. Risk-based monitoring approaches focus resources on critical data and processes while reducing routine source data verification.

Quality Management Systems should address:

• Standard Operating Procedures (SOPs) for all study activities
• Training programs with competency requirements
• Document control systems ensuring current versions are in use
• Corrective and Preventive Action (CAPA) procedures for addressing findings

Sources

1. E6(R3) Good Clinical Practice Guidance for Industry - Updated FDA guidance implementing ICH GCP requirements
2. FDA Clinical Trials Guidance Documents - Comprehensive collection of FDA clinical trial guidance
3. GCP Essential Documents Toolkit - Practical guide to regulatory documentation requirements
4. Human Research Study Startup Checklist - Institutional checklist covering startup requirements
5. Clinical Trial Study Startup Resources - Academic medical center startup toolkit